KL-A167

DRUG4 trials

Sponsors

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Conditions

Classical Hodgkin LymphomaNasopharyngeal CarcinomaNon-small Cell Lung CancerRecurrent or MetastaticTriple-negative Breast Cancer and HR+/HER2- BC

Phase 2

An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

CompletedNCT03580564

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Classical Hodgkin Lymphoma

Start: 2018-08-01End: 2022-01-13Updated: 2026-05-05

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

RecruitingNCT05351788

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Non-small Cell Lung Cancer

Start: 2022-05-20End: 2026-12-01Target: 110Updated: 2026-05-12

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

CompletedNCT05445908

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Triple-negative Breast Cancer and HR+/HER2- BC

Start: 2022-08-17End: 2026-07-31Updated: 2026-08-28

Phase 3

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Active, not recruitingNCT05294172

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Nasopharyngeal Carcinoma, Recurrent or Metastatic

Start: 2022-06-07End: 2027-12-01Updated: 2026-05-08

Related Papers

First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial.

2025-08-191 citations

Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.

Journal of Clinical Oncology2025-05-282 citations

Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study.

Journal of Clinical Oncology2025-05-282 citations

Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study.

Journal of Clinical Oncology2025-05-281 citations

Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.

Journal of Clinical Oncology2024-06-0117 citations

Abstract PS08-08: Updated efficacy and safety of SKB264 (MK-2870) for previously treated metastatic triple negative breast cancer (mTNBC) in Phase 2 study

Cancer Research2024-05-024 citations

Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study.

2022-10-1021 citations